Please check your internet connection and try again.
# Hepamerz (L-Ornithine L-Aspartate)
## Overview
Hepamerz is a combination of the amino acids L-ornithine and L-aspartate. It is thought to work by stimulating the detoxification of ammonia in the liver and peripheral tissues.
## Primary Indications
* Treatment of latent and manifest hepatic encephalopathy.
## Adult Dosing
* **Oral:** 3 g (6 tablets or 1 sachet) three times daily.
* **Intravenous:** 5 g to 10 g (1 to 2 ampoules) diluted in 500 mL of infusion solution (e.g., 0.9% NaCl or 5% dextrose) infused over 30 to 60 minutes, typically administered once or twice daily. Higher doses may be used in severe cases. Specific dosing and infusion rates may vary based on local protocols and patient response.
## Pediatric Dosing
Dosing in pediatric patients is not well-established and should be determined by a specialist.
## Dose Adjustments
No specific dose adjustments are routinely recommended for renal or hepatic impairment, as the drug is metabolized differently than other hepatotoxic agents. However, caution is advised in patients with severe renal impairment.
## Contraindications
* Hypersensitivity to L-ornithine L-aspartate or any of its excipients.
* Severe renal insufficiency.
## Adverse Effects
Commonly reported adverse effects include:
* Nausea
* Vomiting
* Abdominal pain
* Diarrhea
* Flatulence
Less common effects include:
* Headache
* Dizziness
* Fatigue
* Skin rash
## Key Drug Interactions
No significant drug interactions have been definitively established. However, co-administration with other drugs that affect ammonia metabolism or renal function should be approached with caution.
## Monitoring
* Monitor for symptoms of hepatic encephalopathy (e.g., confusion, asterixis, changes in consciousness).
* Monitor for gastrointestinal side effects.
* Renal function may be monitored in patients with pre-existing renal impairment.
## Clinical Pearls
* Hepamerz is intended for use in patients with liver disease, particularly those with hyperammonemia.
* Oral administration can be used for long-term management of latent hepatic encephalopathy.
* Intravenous administration is typically used for more acute or severe forms of hepatic encephalopathy.
* The efficacy and safety in pediatric populations are not well-established.
***
**Disclaimer:** This information is intended for healthcare professionals and is not a substitute for professional medical advice. Always consult the most current prescribing information and your healthcare provider for any medical decisions.
